Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study

Yu Zhang, Shuo Cao, Nan Niu, Huilian Shan, Jinqi Xue, Guanglei Chen, Yongqing Xu, Jianqiao Yin, Chao Liu, Lisha Sun, Xiaofan Jiang, Meiyue Tang, Qianshi Xu, Mingxuan Jia, Xu Zhang, Zhenyong Zhang, Qingfu Zhang, Jianfei Wang, Ailin Li, View ORCID ProfileYongliang Yang, View ORCID ProfileCaigang Liu
doi: https://doi.org/10.1101/2024.08.31.24312890
Yu Zhang
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
3Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China
4Department of Gastrointestinal Surgery, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuo Cao
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nan Niu
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
3Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huilian Shan
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinqi Xue
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
3Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guanglei Chen
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
3Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongqing Xu
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianqiao Yin
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chao Liu
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
3Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisha Sun
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
3Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaofan Jiang
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
3Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meiyue Tang
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qianshi Xu
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mingxuan Jia
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xu Zhang
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhenyong Zhang
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qingfu Zhang
5Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianfei Wang
6Jiangsu Hengrui Pharmaceuticals, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ailin Li
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongliang Yang
7School of Bioengineering, Dalian University of Technology, Dalian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yongliang Yang
  • For correspondence: liucg{at}sj-hospital.org
Caigang Liu
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
3Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Caigang Liu
  • For correspondence: liucg{at}sj-hospital.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

Background Both neoadjuvant chemotherapy and endocrine therapy only result in trivial pathological complete response rates and moderate objective response rates (ORR) in hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer, more promising alternatives are urgently needed. With proven synergistic effect of cyclin dependent kinase 4/6 (CDK4/6) inhibitor and radiotherapy in preclinical studies, this pilot study aimed to explore the efficacy and safety of neoadjuvant stereotactic body radiation therapy (SBRT) followed by dalpiciclib and exemestane in HR-positive, HER2-negative breast cancer.

Methods This was a single-arm, non-controlled prospective pilot study. Treatment-naïve patients with unilateral HR-positive, HER2-negative breast cancer received neoadjuvant radiotherapy (24Gy/3F) followed by dalpiciclib and exemestane for 6 cycles. The primary endpoint was the proportion of patients with residual cancer burden (RCB) score of 0-I. Key secondary endpoints included ORR, breast-conservation rate, biomarker analysis, and safety.

Results All 12 enrolled patients completed the study treatment and surgery. Two (16.7%) of them achieved the RCB 0-I with the ORR of 91.7% (11/12). Analyses of tumor specimens showed significant increase of infiltrating T cells rather than alteration of PD-L1 positive immune cells. The most common grade 3 adverse events (AEs) were neutropenia (66.7%) and leukopenia (25.0%), but no grade 4-5 AE or death occurred.

Conclusions Our results suggested neoadjuvant SBRT followed by dalpiciclib and exemestane are effective and tolerable, and provides novel insights for the neoadjuvant treatment of HR+/HER2-breast cancer, which may be considered as a feasible option for patients with HR-positive, HER2-negative breast cancer.

Competing Interest Statement

Jianfei Wang is the employee of Jiangsu Hengrui Pharmaceuticals Co., Ltd. No other potential conflicts of interest were reported.

Clinical Trial

NCT05132790

Funding Statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Institutional Review Board and Ethics Committee of Shengjing Hospital of China Medical University, according to the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was obtained from each patient.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

  • Funding: None

  • Clinical trial number: NCT05132790

  • Impact statement: Neoadjuvant SBRT with dalpiciclib and exemestane resulted in a 16.7% RCB 0-I rate and a 91.7% ORR, with acceptable toxicities in HR-positive, HER2-negative breast cancer patients.

  • This version of the manuscript has been revised to update the following: - The term "early-stage HR-positive, HER2-negative breast cancer" has been revised to "early or locally advanced HR-positive, HER2-negative breast cancer". - The methods section has been updated to include follow-up details, sample size estimation, and the secondary endpoint of breast-conservation rate. - The item "HER2 expression" in Table 1 has been revised from "negative, 1+, 2+ and FISH-" to "0, 1+, 2+ and FISH-". - The breast-conservation rate has been highlighted in both the results and discussion sections. - Emphasized that the main rationale for neoadjuvant medical therapy is surgical downstaging in the discussion section - Revised the description of this regimen to highlight it as a feasible option.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted February 07, 2025.
Download PDF
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study
Yu Zhang, Shuo Cao, Nan Niu, Huilian Shan, Jinqi Xue, Guanglei Chen, Yongqing Xu, Jianqiao Yin, Chao Liu, Lisha Sun, Xiaofan Jiang, Meiyue Tang, Qianshi Xu, Mingxuan Jia, Xu Zhang, Zhenyong Zhang, Qingfu Zhang, Jianfei Wang, Ailin Li, Yongliang Yang, Caigang Liu
medRxiv 2024.08.31.24312890; doi: https://doi.org/10.1101/2024.08.31.24312890
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study
Yu Zhang, Shuo Cao, Nan Niu, Huilian Shan, Jinqi Xue, Guanglei Chen, Yongqing Xu, Jianqiao Yin, Chao Liu, Lisha Sun, Xiaofan Jiang, Meiyue Tang, Qianshi Xu, Mingxuan Jia, Xu Zhang, Zhenyong Zhang, Qingfu Zhang, Jianfei Wang, Ailin Li, Yongliang Yang, Caigang Liu
medRxiv 2024.08.31.24312890; doi: https://doi.org/10.1101/2024.08.31.24312890

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3294)
  • Dentistry and Oral Medicine (364)
  • Dermatology (279)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
  • Epidemiology (13376)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5153)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3269)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (431)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14629)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (477)
  • Medical Ethics (127)
  • Nephrology (523)
  • Neurology (4925)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (724)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4212)
  • Public and Global Health (7504)
  • Radiology and Imaging (1706)
  • Rehabilitation Medicine and Physical Therapy (1013)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)